Post by
ScienceFirst on Mar 30, 2022 11:19am
Rutherrin and more
The table is set.
- Rutherrin has been manufactured (with Alphora (now EuroFin)) and is going through shelf-life certification (just like TLD-1433 had to go through such process in 2015)
- we have Ph. 2b data that shows destruction of solid tumors (NMIBC), in 2 treatments, with no side effects
- we have our Research lab
- we have our portfolio of PDCs (Ru, OS, etc ...)
- we have Prof. McFarland
- we have proof-of-concept data conducted by PHAC’s National Microbiology Laboratory regarding the destruction of viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations. These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.
Comment by
fredgoodwinson on Mar 30, 2022 12:25pm
Thanks for the encouraging update on Rutherrin Science First. The sort of thing that you might expect from the Company and - if coming from them - with a likely positive effect on the sp but that`s something that`s never seemed to concern them.